Integra LifeSciences Holdings Corporation (IART)

Integra LifeSciences beat expectations on earnings while revenue came in line, based on preliminary results for the third fiscal quarter of 2026 reported October 21, 2026. Revenue rose 2.3% to about $411.2 million (up from roughly $402.1 million a year ago), with adjusted EPS of $0.59 topping the $0.56 estimate (+6%), while revenue of $411.2 million was in line with the $413.2 million estimate (-0.5%). Gross profit was about $209.9 million, putting gross margin near 51%, and operating income came in around $18.9 million for an operating margin of roughly 5%, keeping profitability modest relative to sales. The business generated operating cash flow of about $96.0 million over the quarter. Consensus for the next period calls for EPS of $0.69 on revenue of $428.8 million.